Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Agenus ( (AGEN) ) has issued an update.
On March 24, 2026, the U.S. District Court for the District of Massachusetts dismissed in its entirety a putative securities class action against Agenus Inc. and several current and former executives, which had alleged violations of federal securities laws tied to the company’s public disclosures. The ruling, which also denied the plaintiff’s request for leave to amend, removes an overhang of securities litigation risk for Agenus, easing potential legal and financial uncertainties for the company and its stakeholders.
The most recent analyst rating on (AGEN) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.
Spark’s Take on AGEN Stock
According to Spark, TipRanks’ AI Analyst, AGEN is a Neutral.
Overall score is held back primarily by weak financial performance (negative equity and substantial cash burn despite 2025 improvements). Technicals are moderately supportive with price above key averages and positive MACD, and the Zydus collaboration is a notable positive corporate event, but valuation signals are limited due to a non-meaningful P/E and no dividend yield.
To see Spark’s full report on AGEN stock, click here.
More about Agenus
Agenus Inc. operates in the biotechnology and biopharmaceutical industry, focusing on the research and development of immuno-oncology therapies. The company develops treatments that leverage the immune system to combat cancer and targets markets where novel cancer immunotherapies can address significant unmet medical needs.
Average Trading Volume: 634,950
Technical Sentiment Signal: Sell
Current Market Cap: $136.7M
See more data about AGEN stock on TipRanks’ Stock Analysis page.